featured
Doxorubicin Alone vs Doxorubicin With Trabectedin Followed by Trabectedin Alone as First-Line Therapy for Metastatic or Unresectable Leiomyosarcoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
Lancet Oncol 2022 Aug 01;23(8)1044-1054, P Pautier, A Italiano, S Piperno-Neumann, C Chevreau, N Penel, N Firmin, P Boudou-Rouquette, F Bertucci, C Balleyguier, V Lebrun-Ly, I Ray-Coquard, E Kalbacher, A Bardet, E Bompas, O Collard, N Isambert, C Guillemet, M Rios, B Archambaud, F DuffaudFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.